Skip to content
Screener

Operating Income at other companies

Gilead Sciences logo
Gilead SciencesGILD
-$10.39B-520%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-$52.36M-11.4%
LQD
Liquidia CorporationLQDA
$61.5M+274%
ALN
Alnylam PharmaceuticalsALNY
$231.44M+1,529%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$105.96M-1.5%
Arrowhead Research logo
Arrowhead ResearchARWR
-$141.26M-137%

Segments

By segment

See full
Reportable Segment-$42.54M-753%

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Acquired in-process research and development16,435742,7375,000
Selling, general and administrative81,46963,286177,799120,992
Total operating expenses218,780132,7741,168,127259,542
Loss from operations(42,537)(4,989)(832,002)(20,172)
Other income (expense):
Interest income3,8513,0337,2526,056
Interest expense(2,618)(3,589)(6,234)(7,185)
Other (expense) income, net(24,234)86(24,234)2,194

Item 1. Financial Statements (Unaudited)

FAQ

What is Mirum Pharmaceuticals, Inc.'s operating income?
Mirum Pharmaceuticals, Inc. (MIRM) reported operating income of -$42.54M in Q2 2026.
How has Mirum Pharmaceuticals, Inc.'s operating income changed year-over-year?
Mirum Pharmaceuticals, Inc.'s operating income decreased by 752.6% year-over-year, from -$4.99M to -$42.54M.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s operating income?
Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s operating income has grown at a -40.2% compound annual growth rate (CAGR), from -$173.41M to -$22.14M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Mirum Pharmaceuticals, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude